PD-1-PD-L1-Inhibitors-Modulators-生命科学试剂-MedChemExpress.pdf

PD-1/PD-L1 PD-1/Programmed death-ligand 1 Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy. PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs. www.MedChemE 1 PD-1/PD-L1 Inhibitors, Antagonists Activators ARB-272572 Atezolizumab Cat. No.: HY-142221 (MPDL3280A) Cat. No.: HY-P9904 ARB-272572 is a potent small-molecule PD-L1 Atezolizumab (MPDL3280A) is a selective humanized inhibitor with an IC50 value of 400pM.